
Loading, please wait...

Loading, please wait...

Acute-on-chronic liver failure represents a devastating clinical syndrome marked by rapid hepatic decompensation and intense systemic inflammation. In intensive care units, clinicians frequently utilize extracorporeal liver support to mitigate organ dysfunction and stabilize decompensated patients. A prospective observational study from Vietnam now provides critical real-world evidence on patient outcomes. Specifically, the investigation evaluates clinical parameters that predict short-term recovery in patients receiving advanced extracorporeal therapies.
Acute-on-chronic liver failure triggers profound systemic collapse in patients with pre-existing chronic liver disease. The condition initiates an uncontrolled release of pro-inflammatory cytokines, marked endotoxemia, and severe circulatory dysfunction. Consequently, patients rapidly develop multiorgan failure, with acute kidney injury and coagulopathy posing immediate mortality risks. In Asia, chronic hepatitis B flares and alcohol-induced liver injury represent the primary triggers.
Standard medical therapy frequently fails to reverse this self-amplifying hyperinflammatory cycle. Therefore, artificial liver purification platforms provide crucial therapeutic assistance in intensive care units. These advanced systems actively remove albumin-bound toxins, water-soluble metabolites, and circulating inflammatory mediators. By attenuating systemic inflammation, clinicians hope to foster native hepatocyte regeneration. Alternatively, these modalities stabilize hemodynamics to bridge patients toward urgent liver transplantation. However, clinicians must carefully select candidates who can achieve meaningful clinical recovery. Identifying dependable prognostic factors remains imperative to guide treatment escalation and optimize resource utilization.
Researchers at Bach Mai Hospital in Vietnam conducted a prospective observational cohort study enrolling seventy consecutive ACLF patients. The multidisciplinary clinical team managed all patients using a dedicated extracorporeal protocol. Specifically, clinicians allocated thirty-five patients to high-volume plasma exchange based on institutional expertise. Meanwhile, the team treated the remaining thirty-five patients with a double plasma molecular adsorption system paired with low-volume plasma exchange.
The study investigators established rigorous procedural intervals to record longitudinal laboratory changes. They obtained blood samples immediately before therapy, directly after removing adsorption cartridges, and at full procedural completion. Notably, treating physicians determined modality allocation pragmatically rather than through randomized selection. High-volume plasma exchange replaces vast plasma volumes, clearing circulating toxins while replenishing essential clotting factors. Conversely, the molecular adsorption circuit uses specialized resin cartridges to capture bilirubin and cytokines selectively. Adding low-volume plasma exchange replenishes coagulants while conserving donor blood products. Both purification strategies demonstrated procedural safety and clinical feasibility in this critically ill cohort.
The observational cohort demonstrated an encouraging overall 28-day survival rate of 92.9 percent. However, successful clinical recovery at hospital discharge occurred in only 37.1 percent of patients. This notable divergence underscores that short-term survival does not equal complete clinical recovery. Furthermore, researchers identified critical baseline parameters that separated recovering patients from those experiencing persistent liver dysfunction.
Specifically, successful recovery strongly correlated with significantly lower baseline systemic inflammation. Recovering individuals presented with lower neutrophil percentages and reduced interleukin-6 levels. Preserved renal function was equally paramount, as lower baseline serum creatinine strongly favored hospital discharge. In addition, patients achieving discharge recovery exhibited significantly higher baseline serum bicarbonate, higher platelet counts, and higher prothrombin activity percentages. Lower baseline organ failure scores also consistently predicted favorable clinical trajectories. Conversely, uncontained systemic inflammation and metabolic acidosis indicated severe risk. These biochemical associations confirm that lower inflammatory burden and intact renal function represent essential prerequisites for functional recovery.
Serial laboratory monitoring across procedural time points offered valuable perspectives on clearance dynamics. Both blood purification modalities achieved marked reductions in circulating total bilirubin immediately after treatment. The adsorption cartridges rapidly cleared bile pigments and toxic metabolites, while plasma exchange diluted accumulated toxins. In addition to bilirubin reduction, both protocols significantly lowered circulating pro-inflammatory mediators.
Nevertheless, clinicians must interpret these descriptive trajectories with appropriate caution. Because the study design did not randomize treatment modalities, the findings cannot determine comparative therapeutic superiority. Furthermore, acute biochemical clearance does not automatically translate into permanent hepatic regeneration. Blood purification effectively clears toxic metabolites from the circulation, but it cannot restore complex synthetic function. Patients with adequate underlying liver reserve sustained post-procedure improvements effectively. In contrast, patients with extensive hepatocellular necrosis experienced rapid biochemical rebound following therapy cessation. Consequently, clinicians must utilize dynamic post-procedure biomarker monitoring to evaluate whether patients require subsequent purification sessions or immediate transplant listing.
The findings from this Asian cohort offer highly relevant lessons for intensivists and hepatologists across India. Acute-on-chronic liver failure represents a significant clinical burden in Indian intensive care units. In this population, acute alcohol-associated hepatitis and viral hepatitis reactivation trigger most decompensations. Given the severe shortage of donor organs across India, extracorporeal detoxification serves as an essential supportive bridge.
Furthermore, blood product availability remains a major operational challenge in many Indian tertiary hospitals. High-volume plasma exchange consumes substantial quantities of fresh frozen plasma, creating logistical strain and increasing transfusion-related risks. Consequently, combining double plasma molecular adsorption with low-volume plasma exchange offers an attractive alternative. This hybrid strategy provides robust cytokine and bilirubin removal while conserving scarce plasma reserves. Moreover, recognizing baseline prognostic indicators helps Indian clinicians triage candidates effectively. Patients presenting with uncontrolled systemic inflammation, advanced renal failure, and poor acid-base balance require expedited transplant listing rather than repeated artificial purification attempts.
Extracorporeal liver support acts as a vital bridge therapy for acute-on-chronic liver failure. It temporarily assumes hepatic detoxification functions to prevent multi-organ failure. By eliminating protein-bound toxins, circulating endotoxins, and systemic inflammatory mediators, these systems mitigate systemic inflammation. Consequently, this intervention stabilizes hemodynamics and creates a therapeutic window for spontaneous native liver regeneration or liver transplantation. Clinicians often deploy high-volume plasma exchange or adsorption circuits when standard medical therapy fails to arrest deterioration.
Successful clinical recovery correlates closely with lower systemic inflammatory activity and preserved end-organ function. Specifically, lower circulating interleukin-6 levels and lower neutrophil percentages indicate attenuated inflammatory cascades. Furthermore, lower serum creatinine and robust serum bicarbonate levels demonstrate preserved renal performance and normal acid-base homeostasis. In contrast, higher platelet counts and higher prothrombin activity reflect preserved hepatic synthetic capacity. Clinicians rely on these combined laboratory indicators alongside validated severity scores to assess short-term prognosis accurately.
High-volume plasma exchange replaces large volumes of patient plasma with donor plasma, replenishing vital coagulation factors while clearing toxins. Conversely, double plasma molecular adsorption system combines neutral resin and anion-exchange resin cartridges to capture bilirubin and inflammatory cytokines directly from separated plasma. Adding low-volume plasma exchange provides essential coagulation factors without requiring massive fresh frozen plasma supplies. Thus, this combined modality conserves valuable blood products while delivering targeted molecular clearance in resource-constrained critical care units.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A prospective cohort study evaluated 70 ACLF patients receiving extracorporeal liver support in Vietnam. Findings showed a 92.9% 28-day survival rate, with discharge recovery linked to lower baseline inflammation, preserved renal function, and higher platelet counts.
Today

A rare presentation of severe fetal anemia and pancytopenia in maternal systemic lupus erythematosus was successfully managed using serial intrauterine transfusions and IVIG, leading to a favorable neonatal outcome without postnatal transfusions.
Today

A new scoping review and expert consensus establish a concise 16-measure performance bundle for hospital cardiology services. Covering clinical processes, outcomes, patient-reported experiences, and structural factors, this framework advances value-based cardiovascular care under universal health coverage.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Today

New research links de novo truncating variants in ZNF462 to congenital hypogonadotropic hypogonadism and Kallmann syndrome in Weiss-Kruszka syndrome. These findings reveal critical neurodevelopmental and epigenetic mechanisms governing GnRH neuron deficiency, offering new diagnostic clarity for clinicians.
Today